Back

Mechanisms of the clinical benefits of SGLT2i in heart failure (EMPEROR-Pooled)

26 August 2022 (11:15 - 11:30)
Organised by:
Congress Presentation Part of: Late-Breaking Science - Innovations in drug treatment Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Faiez Zannad

University of Lorraine, Vandoeuvre-Les-Nancy (France)

3 More presentations in this session

Presentation thumbnail
Lifetime prediction and Treatment Benefit in HFrEF (LIFE-HF).
Doctor S. Koudstaal (Gouda, NL)
Slides Video
Presentation thumbnail
Genotype-Guided Oral P2Y12 Inhibitor Therapy Reduces Cumulative Ischemic Events Following Percutaneous Coronary Intervention - A Prespecified Secondary Analysis of the TAILOR-PCI Randomised Trial
Doctor B. Ingraham (Rochester, US)
Slides Video
Presentation thumbnail
ENTRIGUE: Pegozafermin for the treatment of severe hypertriglyceridemia.
Professor D. Bhatt (New York City, US)
Slides Video

Access the full session

Session thumbnail
Late-Breaking Science - Innovations in drug treatment
Video

The Event

Event poster

ESC Congress 2022

26 August 2022 11:15 CET
You may be interested in
thumbnail
Congress Session
Diabetes, obesity, and heart failure
thumbnail
Congress Presentation
Effects of empagliflozin on cardio-renal interaction in heart failure with reduced ejection fraction: results from in-vivo experiments and the CINNAMON-study
thumbnail
Congress Presentation
Comparison of sodium-glucose cotransporter-2 (SGLT2) inhibitors to reduce cardiovascular and renal outcomes: a network meta-analysis of randomized controlled trials

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources